NurExone Biologic Inc.
NRX.V
Toronto Stock Exchange Ventures0.55
CAD
- -
- -
ISIN
CA67059R1091
CUSIP
67059R109
Return %
Stock
S&P500
1Y
-19.12
19.99
3Y
100.00
69.40
5Y
27.91
72.03
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Lior Shaltiel
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 1 Adelaide Street East Toronto ON Canada M5C 2V9
- IPO Date
- Sep 13, 2022
- Website
- nurexone.com
- Similar Companies
- Business
- NurExone Biologic Inc. is a biotechnology company focused on developing regenerative exosome-based therapies for central nervous system injuries, using its ExoTherapy platform to create exosome-loaded nanodrugs and to pursue minimally invasive, targeted delivery solutions; it advances ExoPTEN, an exosome-based therapy for acute spinal cord injury, and pursues membrane-bound extracellular vesicle approaches for other neurological conditions, including traumatic brain injury and glaucoma. The company operates primarily through a two-line business model: developing internally its CNS-targeted ExoTherapy-derived products and licensing or partnering the ExoTherapy platform with global biopharmaceutical companies for other indications. NurExone aims to commercialize its lead product ExoPTEN and expand its pipeline via collaborations, licensing agreements, and strategic partnerships. The company was founded in 2020 and is headquartered in Toronto, Canada, with a public listing on the TSX Venture Exchange under the ticker NRX (and on OTC markets as NRXBF), reflecting its cross-border investor visibility and growth strategy. Its technology centers on extracellular vesicle–based drug delivery systems designed for minimally invasive administration and tissue-specific regeneration, positioning NurExone within the CNS repair and neuroregeneration segment of the biotechnology industry. Subsidiaries and corporate structures align with licensing and collaboration models to scale ExoTherapy beyond the lead program, targeting global markets and regulatory pathways in major jurisdictions. The company’s geographic footprint includes Canada and international collaboration reach, with strategic focus on partnering with biopharma developers to broaden indications and accelerate clinical development pipelines.